Akari Therapeutics (AKTX, Financial), a biopharmaceutical company focused on innovative therapeutics, has recently garnered attention as Maxim Group initiates coverage with a "Buy" rating. The announcement, spearheaded by analyst Jason McCarthy, highlights the promising future anticipated for the company.
In the latest analyst report dated July 18, 2025, Maxim Group has set a price target of $5.00 USD for Akari Therapeutics (AKTX, Financial). This target reflects the firm's confidence in the potential growth and market performance of the company.
The stock's initiation with this favorable rating comes without any previous rating or price target changes, marking a significant step for Akari Therapeutics (AKTX, Financial) as it continues to advance its development programs.
Investors and market followers are keeping a close watch on Akari Therapeutics (AKTX, Financial) following this development, as the company's initiatives and future prospects are set under a positive light from the analyst community.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Akari Therapeutics PLC (AKTX, Financial) is $7.00 with a high estimate of $7.00 and a low estimate of $7.00. The average target implies an upside of 524.61% from the current price of $1.12. More detailed estimate data can be found on the Akari Therapeutics PLC (AKTX) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Akari Therapeutics PLC's (AKTX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
